Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women

A J Proudler; A I Ahmed; D Crook; I Fogelman; J M Rymer; J C Stevenson

doi:10.1016/s0140-6736(95)92114-1

Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women

Lancet. 1995 Jul 8;346(8967):89-90. doi: 10.1016/s0140-6736(95)92114-1.

Authors

A J Proudler¹, A I Ahmed, D Crook, I Fogelman, J M Rymer, J C Stevenson

Affiliation

¹ Wynn Department of Metabolic Medicine, National Heart and Lung Institute, London, UK.

PMID: 7603219
DOI: 10.1016/s0140-6736(95)92114-1

Abstract

The mechanisms by which hormone replacement therapy (HRT) reduces the risk of coronary heart disease (CHD) are incompletely understood, but may include direct arterial effects. We examined the effect of oestrogen/progestagen HRT on serum angiotensin-converting-enzyme (ACE) activity in postmenopausal women. After 6 months, ACE activity was reduced by 20% (p < 0.001) on average in 28 treated women but remained unchanged in 16 controls. Serum ACE activity is modifiable by gonadal steroids and changes in serum ACE may represent a novel mechanism by which HRT reduces CHD risk in women.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Coronary Disease / prevention & control
Estradiol / administration & dosage
Estradiol / analogs & derivatives
Estradiol / therapeutic use
Estrogen Replacement Therapy*
Estrogens, Conjugated (USP) / administration & dosage
Estrogens, Conjugated (USP) / therapeutic use
Female
Humans
Middle Aged
Norethindrone / administration & dosage
Norethindrone / therapeutic use
Peptidyl-Dipeptidase A / blood*
Postmenopause / blood*
Prospective Studies
Risk Factors

Substances

Estrogens, Conjugated (USP)
Estradiol
Peptidyl-Dipeptidase A
Norethindrone